Altimmune Inc
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedAltimmune Inc (ALT) Insider Trades
ALT Insider Trading Activity
Track insider trading transactions for Altimmune Inc (ALT). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $2.82. Market cap: $294.00M. This page displays the most recent insider transactions for ALT, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Altimmune Inc's investment outlook.